98 related articles for article (PubMed ID: 27658341)
1. Hypoadiponectinemia, elevated iron and high-sensitivity C-reactive protein levels and their relation with prostate size in benign prostatic hyperplasia.
Nandeesha H; Eldhose A; Dorairajan LN; Anandhi B
Andrologia; 2017 Sep; 49(7):. PubMed ID: 27658341
[TBL] [Abstract][Full Text] [Related]
2. Elevated insulin and reduced insulin like growth factor binding protein-3/prostate specific antigen ratio with increase in prostate size in Benign Prostatic Hyperplasia.
Sreenivasulu K; Nandeesha H; Dorairajan LN; Rajappa M; Vinayagam V
Clin Chim Acta; 2017 Jun; 469():37-41. PubMed ID: 28300542
[TBL] [Abstract][Full Text] [Related]
3. Association of elevated interleukin-17 and angiopoietin-2 with prostate size in benign prostatic hyperplasia.
Arivazhagan J; Nandeesha H; Dorairajan LN; Sreenivasulu K
Aging Male; 2017 Jun; 20(2):115-118. PubMed ID: 28590830
[TBL] [Abstract][Full Text] [Related]
4. Lipoproteins, sex hormones and inflammatory markers in association with prostate cancer.
Grosman H; Fabre B; Mesch V; Lopez MA; Schreier L; Mazza O; Berg G
Aging Male; 2010 Jun; 13(2):87-92. PubMed ID: 19921964
[TBL] [Abstract][Full Text] [Related]
5. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer.
Lehrer S; Diamond EJ; Mamkine B; Droller MJ; Stone NN; Stock RG
BJU Int; 2005 May; 95(7):961-2. PubMed ID: 15839913
[TBL] [Abstract][Full Text] [Related]
6. Estimation levels of prostate-specific antigen, interleukin-8, oxidative stress and some inflammatory markers in sera of benign prostatic hyperplasia patients who have smoking habits as a risk factor.
Al-Barzinj RMGT
Cell Mol Biol (Noisy-le-grand); 2020 Oct; 66(7):124-130. PubMed ID: 33287932
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
9. Serum C-reactive protein levels are associated with residual urgency symptoms in patients with benign prostatic hyperplasia after medical treatment.
Liao CH; Chung SD; Kuo HC
Urology; 2011 Dec; 78(6):1373-8. PubMed ID: 21962879
[TBL] [Abstract][Full Text] [Related]
10. Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.
Schenk JM; Kristal AR; Neuhouser ML; Tangen CM; White E; Lin DW; Thompson IM
Prostate; 2009 Sep; 69(12):1303-11. PubMed ID: 19475640
[TBL] [Abstract][Full Text] [Related]
11. Serum amyloid A, phospholipase A₂-IIA and C-reactive protein as inflammatory biomarkers for prostate diseases.
Menschikowski M; Hagelgans A; Fuessel S; Mareninova OA; Asatryan L; Wirth MP; Siegert G
Inflamm Res; 2013 Dec; 62(12):1063-72. PubMed ID: 24061501
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of serum protein-bound sialic acid in benign and malignant prostatic growth: possible role of oxidative stress in sialic acid homeostasis.
Goswami K; Nandeesha H; Koner BC; Nandakumar DN
Prostate Cancer Prostatic Dis; 2007; 10(4):356-9. PubMed ID: 17404581
[TBL] [Abstract][Full Text] [Related]
13. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
Stephan C; Lein M; Jung K; Schnorr D; Loening SA
Cancer; 1997 Jan; 79(1):104-9. PubMed ID: 8988733
[TBL] [Abstract][Full Text] [Related]
14. Significance of obesity markers and adipocytokines in high grade and high stage prostate cancer in North Indian men - a cross-sectional study.
Tewari R; Rajender S; Natu SM; Goel A; Dalela D; Goel MM; Tondon P
Cytokine; 2013 Aug; 63(2):130-4. PubMed ID: 23669251
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
Khosravi J; Diamandi A; Mistry J; Scorilas A
J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033
[TBL] [Abstract][Full Text] [Related]
16. Serum adipocytokine levels in prostate cancer patients.
Arisan ED; Arisan S; Atis G; Palavan-Unsal N; Ergenekon E
Urol Int; 2009; 82(2):203-8. PubMed ID: 19322011
[TBL] [Abstract][Full Text] [Related]
17. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
18. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA.
Ozden C; Inal G; Adsan O; Yazici S; Ozturk B; Cetinkaya M
Urol Int; 2003; 71(2):150-3. PubMed ID: 12890951
[TBL] [Abstract][Full Text] [Related]
19. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
[TBL] [Abstract][Full Text] [Related]
20. Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men.
Liu CC; Huang SP; Li WM; Wang CJ; Chou YH; Li CC; Huang CH; Wu WJ
Urology; 2007 Oct; 70(4):677-80. PubMed ID: 17991536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
